Silver nanoparticles induce a non-immunogenic tumor cell death

Area of Science:

• Nanotechnology
• Immunology
• Oncology

Background:

• Immunogenic cell death (ICD) is crucial for adaptive immune responses against cancer.
• Silver nanoparticles (AgNP) exhibit anti-proliferative and cytotoxic properties against tumor cells.
• The potential of AgNP to induce ICD and its in vivo anti-cancer effects remain largely unexplored.

Purpose of the Study:

• To evaluate the in vitro release of calreticulin, a damage-associated molecular pattern (DAMP), as a marker of AgNP-induced cytotoxicity.
• To assess the in vivo anti-cancer effects of AgNP through immunization and direct tumor administration.
• To determine if AgNP can act as an immunogenic cell death inducer.

Main Methods:

• In vitro studies exposed CT26 colon carcinoma and MCA205 fibrosarcoma cells to AgNP to assess proliferation, adhesion, and calreticulin release.
• In vivo studies monitored tumor growth and survival in mice after vaccination with AgNP-treated tumor cells or direct intra-tumoral AgNP injection.
• Doxorubicin was used as a positive control for DAMP detection.

Main Results:

• AgNP demonstrated time- and concentration-dependent anti-proliferative effects in both CT26 and MCA205 cell lines.
• Calreticulin release, a marker of ICD, was significantly increased in CT26 cells treated with AgNP, but not in MCA205 cells.
• In vivo, AgNP-based immunization failed to protect against tumor re-challenge, and intra-tumoral AgNP injection showed no significant anti-tumor effect.

Conclusions:

• AgNP exhibit in vitro anti-tumor activity and can induce calreticulin release in specific cancer cell lines.
• The in vivo anti-cancer efficacy of AgNP, particularly as an ICD inducer, was not confirmed in this study.
• Further investigation is warranted to explore combination therapies involving AgNP with other ICD inducers to improve in vivo anti-cancer outcomes.